The cut-off value for interleukin 34 as an additional potential inflammatory biomarker for the prediction of the risk of diabetic complications

References

• Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, et al (2013). Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013:976810
   PubMed Web of Science ®Google Scholar
• Bermúdez V, Rojas J, Salazar J, et al (2015). Sensitivity and specificity improvement in abdominal obesity diagnosis using cluster analysis during waist circumference cut-off point selection. J Diabetes Res 2015:750265
   PubMed Web of Science ®Google Scholar
• Carpenter J, Bithell J. (2000). Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19:1141–64
   PubMed Web of Science ®Google Scholar
• Chang EJ, Lee SK, Song YS, et al (2014). IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab 99:E1263–71
   PubMed Web of Science ®Google Scholar
• Chemel M, Le Goff B, Brion R, et al (2012). Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis 71:150–4
   PubMed Web of Science ®Google Scholar
• Chen Z, Buki K, Vaaraniemi J, et al (2011). The critical role of IL34 in osteoclastogenesis. PLoS One 6:e18689
   PubMed Web of Science ®Google Scholar
• Daniele G, Guardado Mendoza R, et al (2014). The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–8
   PubMed Web of Science ®Google Scholar
• Del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, et al (2011). Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinol Nutr 58:163–8
   PubMedGoogle Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 44:837–42
   PubMed Web of Science ®Google Scholar
• ETDRS Research Group, ETDRS Report No 11 (1991). Classification of diabetic retinopathy from fluorescein angiograms. Ophthalmology 98:807–22
   PubMed Web of Science ®Google Scholar
• Firdous S. (2014). Correlation of CRP, fasting serum triglycerides and obesity as cardiovascular risk factors. J Coll Physicians Surg Pak 24:308–13
   PubMed Web of Science ®Google Scholar
• Greter M, Lelios I, Pelczar P, et al (2012). Stroma-derived inerleukin 34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity 37:1050–60
   PubMed Web of Science ®Google Scholar
• Hafiane A, Kellett S, Genest J. (2014). Treatment options for low high-density lipoproteins. Curr Opin Endocrinol Diabetes Obes 21:134–9
   PubMed Web of Science ®Google Scholar
• Halcox JP, Roy C, Tubach F, et al (2014). C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord 14:25
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Choi B, Kang SS, et al (2012). Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther 14:R14
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF) Diabetes Atlas. Available at: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf
   Google Scholar
• Kluzek S, Arden NK, Newton J. (2015). Adipokines as potential prognostic biomarkers in patients with acute knee injury. Biomarkers 26:1–7
   Google Scholar
• Li Z, Jin D, Wu Y, et al (2012). Increased serum interleukin-34 in patients with coronary artery disease. J Int Med Res 40:1866–70
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I. (2013). Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 7:e330–41
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. (2011). Fenofibrate: a review of its use in dyslipidaemia. Drugs 71:1917–46
   PubMed Web of Science ®Google Scholar
• Mora S, Ridker PM. (2006). Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97:33A–41A
   PubMed Web of Science ®Google Scholar
• Myśliwska J, Zorena K, Myśliwiec M, et al (2009). The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res 66:341–5
   PubMed Web of Science ®Google Scholar
• Ofstad AP, Gullestad L, Orvik E, et al (2013). Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum cardiovascular diabetes (ABCD) cohort study. Cardiovasc Diabetol 12:126. DOI: 10.1186/1475-2840-12-126
   PubMed Web of Science ®Google Scholar
• Pal GK, Adithan C, Ananthanarayanan PH, et al (2013). Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics. PLoS One 8:e78072
   PubMed Web of Science ®Google Scholar
• Patry-Parisien J, Shields M, Bryan S. (2012). Comparison of waist circumference using the world health organization and national institutes of health protocols. Health Rep 23:53–60
   PubMed Web of Science ®Google Scholar
• Position of the Polish Diabetes Association (2014). “Clinical recommendations for treatment of patients with diabetes”. Clin Diabetol (suppl A) 3:A1–A71
   Google Scholar
• Rathcke CN, Vestergaard H. (2009). YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8:61. DOI: 10.1186/1475-2840-8-61
   PubMed Web of Science ®Google Scholar
• Report of WHO Consultation of Obesity. Geneva 3-5 June 1997. (2012 Aug 3). WHO/NUT/NCD 1998. BMC Med Res Methodol. 12:115
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–65
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al (2014). ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC); European association for the study of diabetes (EASD). Diab Vasc Dis Res 11:133–73
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al (2014). Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129:999–1008
   PubMed Web of Science ®Google Scholar
• Tomić M, Ljubić S, Kaštelan S, et al (2013). Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators Inflamm 2013:818671
   PubMed Web of Science ®Google Scholar
• Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, et al (2013). Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 36:723–8
   PubMed Web of Science ®Google Scholar
• WHO: Definition. Diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1 (2006). Diagnosis and classification of diabetes mellitus. WHO. Geneva
   Google Scholar
• Yeh ET, Willerson JT. (2003). Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107:370–1
   PubMed Web of Science ®Google Scholar
• Youden WJ. (1950). Index for rating diagnostic tests. Cancer 3:32–5
   PubMed Web of Science ®Google Scholar
• Zorena K, Kula M, Malinowska E, et al (2013a). Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Hum Immunol 74:75–81
   PubMed Web of Science ®Google Scholar
• Zorena K, Malinowska E, Raczyńska D, et al (2013b). Serum concentrations of transforming growth factor-Beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J Diabetes Res 2013:614908
   PubMed Web of Science ®Google Scholar